A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
List view / Grid view
1 May 2014 | By Nova Laboratories
UK pharmaceutical firm Nova Laboratories has secured U.S Food and Drug Administration approval for its acute lymphoblastic leukaemia (ALL) product Xaluprine...
Nova Laboratories announces FDA filing of New Drug Application for the treatment of childhood acute lymphoblastic leukemia
4 December 2013 | By Nova Laboratories
The product has been granted orphan drug designation by the FDA, a status given to a product intended for the treatment of a rare disease or condition...